Key clinical point: Fat grafting appears to be safe in sarcoma patients, based on local or distant spread and overall survival.
Main finding: At follow-up after fat grafting (2.4 years), one patient had distant metastasis and two had local relapse. Kaplan-Meier analysis showed disease-free survival of 95.4% (CI:89.1-100.0) at 24 months. The risk of local recurrence within 24 months was 4.6% (CI:0.0-20.9). The probability of not having local recurrence after fat grafting was over 89%. Overall median follow-up was 7.5 years.
Study details: Sixty consecutive patients who were recurrence free and underwent 143 fat grafting procedures after surgical resection of bone and soft tissue sarcomas of the head, trunk, and limbs with clear resection margins at a single treatment center.
Disclosures: The authors had no relevant conflicts of interest.
Source: Pennati A et al. Journal of Plastic, Reconstructive & Aesthetic Surgery: Published online 8 August 2018 https://doi.org/10.1016/j.bjps.2018.07.028
Pennati A et al. Journal of Plastic, Reconstructive & Aesthetic Surgery: Published online 8 August 2018 https://doi.org/10.1016/j.bjps.2018.07.028
This Week's Must Reads
Case studies shed light on treatment for rare form of MCL , Mori S et al. Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):e93-7.
Histopathological clues for differentiating follicular lymphomas, Servitje O et al. J Cutan Pathol. 2019;46:182-9.
Single agent daratumumab is not an option in B-cell lymphomas, Salles G et al. Clin Lymphoma Myeloma Leuk. 2019 Jan 2. doi: 10.1016/j.clml.2018.12.013.
Ibrutinib combo advances in CNS lymphoma, Grommes C et al. Blood. 2019;133(5):436-45.
Best frontline options for advanced follicular lymphoma, Shah NN et al. Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):95-102.
Must Reads in Sarcoma & GIST
Intensity modulated radiation therapy may be preferable in children with extremity nonrhabdomyosarcoma soft-tissue sarcomas, Source: Rao A et al. Intl J Rad Oncology*Biology*Physics; Jan. 2019, 38-44. https://doi.org/10.1016/j.ijrobp.2018.09.005
Expanded genetic analyses of myxofibrosarcomas may guide precision therapies, Ogura K et al. Nature Communications; 17 July 2018. https://doi.org/10.1038/s41467-018-03891-9
Malignant tenosynovial giant cell tumors appear to originate from synoviocytes, Al-Ibraheemi A et al. Modern Pathology; 11 Sept. 2018. https://doi.org/10.1038/s41379-018-0129-0
Type and rate of clonal evolution vary widely in sarcoma pathogenetic subgroups, Hofvander J et al. Nature Communications 10 Sept. 2018. https://doi.org/10.1038/s41467-018-06098-0
Increasing pannexin 1 levels might be a novel treatment for rhabdomyosarcoma , Xiang X et al. Oncogenesis; 21 Nov. 2018. https://doi.org/10.1038/s41389-018-0100-4